Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Marshall Lucia to Neoplasm Grading

This is a "connection" page, showing publications Marshall Lucia has written about Neoplasm Grading.

 
Connection Strength
 
 
 
0.986
 
  1. Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS. Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. Arch Pathol Lab Med. 2013 Dec; 137(12):1740-6.
    View in: PubMed
    Score: 0.405
  2. Nir G, Hor S, Karimi D, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Wilson RS, Iczkowski KA, Lucia MS, Black PC, Abolmaesumi P, Goldenberg SL, Salcudean SE. Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts. Med Image Anal. 2018 12; 50:167-180.
    View in: PubMed
    Score: 0.141
  3. Lucia MS, Bokhoven Av. Temporal changes in the pathologic assessment of prostate cancer. J Natl Cancer Inst Monogr. 2012 Dec; 2012(45):157-61.
    View in: PubMed
    Score: 0.095
  4. Iczkowski KA, Molina M, Egevad L, Bostwick DG, van Leenders GJLH, La Rosa FG, van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Leite KRM, Samaratunga H, Srigley J, Varma M, Tsuzuki T, Lucia MS, Crawford ED, Harris RG, Stricker P, Lawrentschuk N, Woo HH, Fleshner NE, Shore ND, Yaxley J, Bratt O, Wiklund P, Roberts M, Cheng L, Delahunt B. Low-grade prostate cancer should still be labelled cancer. BJU Int. 2022 12; 130(6):741-743.
    View in: PubMed
    Score: 0.047
  5. Stanton WN, Crawford ED, Arangua PB, La Rosa FG, van Bokhoven A, Lucia MS, Poage WL, Partin A, Maroni P, Werahera PN. Assessment of high-grade prostate cancer risk using prostate cancer biomarkers. Can J Urol. 2020 02; 27(1):10080-10085.
    View in: PubMed
    Score: 0.039
  6. Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, Parnes HL, LeBlanc ML, Thompson IM. Long-Term Effects of Finasteride on Prostate Cancer Mortality. N Engl J Med. 2019 01 24; 380(4):393-394.
    View in: PubMed
    Score: 0.036
  7. Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer Prev Res (Phila). 2019 02; 12(2):113-120.
    View in: PubMed
    Score: 0.036
  8. Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate. 2017 Jun; 77(8):908-919.
    View in: PubMed
    Score: 0.032
  9. Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate. 2016 09; 76(12):1120-9.
    View in: PubMed
    Score: 0.030
  10. Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 2015 Mar 15; 75(6):1021-34.
    View in: PubMed
    Score: 0.028
  11. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014 May; 23(5):847-56.
    View in: PubMed
    Score: 0.026
  12. Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013 Aug 15; 369(7):603-10.
    View in: PubMed
    Score: 0.025
  13. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May; 73(7):778-87.
    View in: PubMed
    Score: 0.024
  14. Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O'Donnell C, Sidhu RS, Sullivan HT, Schulte B, Crawford ED. Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. Int J Clin Exp Pathol. 2012; 5(9):892-9.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)